References
- Canonica GW, Senna G, Mitchell PD, et al. Therapeutic interventions in severe asthma. World Allergy Organ J 2016;9:40
- Varsano S, Segev D, Shitrit D. Severe and non-severe asthma in the community. A large electronic data base analysis. Resp Med 2017;123:131-9
- Chen S, Golam S ,Myers J, et al. Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment. Curr Med Res Opin 2018;16:1-14
- Hekking PP, Wener RR, Amelink M, et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol 2015;135:896-902
- Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343-73
- Vianello A, Caminati M, Crivellaro M, et al. Fatal asthma; is it still an epidemic? World Allergy Org J 2016;14:42
- Caminati M, Bettoncelli G, Magnoni MS, et al. The level of control of mild asthma in general practice an observational community-based study. J Asthma 2014;51:91-6
- Caminati M, Vianello A, Ricci G, et al. Trends and determinants of ER admissions for asthma: a retrospective evaluation in the north east of Italy. WAO J [submitted for publication]
- Radermecker C, Louis R, Bureau F, et al. Role of neutrophils in allergic asthma. Curr Opin Immunol 2018;54:28-34
- Caminati M, Senna G, Stefanizzi G, et al.; North East Omalizumab Network study group. Drop-out rate among patients treated with omalizumab for severe asthma: literature review and real-life experience. BMC Pulm Med 2016;16:128
- Kerkhof M, Tran TN, van den Berge M, et al. Association between blood eosinophil count and risk of readmission for patients with asthma: historical cohort study. PLoS One 2018;25;13:1-5
- Mathur SK, Fichtinger PS, Evans MD, et al. Variability of blood eosinophil count as an asthma biomarker. Ann Allergy Asthma Immunol 2016;117:551-3
- Ojanguren I, Chaboillez S, Lemiere C. Low blood eosinophil counts are not always a reliable marker of clinical response to mepolizumab in severe asthma. J Allergy Clin Immunol Pract 2018;30:S2213-S2198
- Humbert M, Busse W, Hanania NA. Controversies and opportunities in severe asthma. Curr Opin Pulm Med 2018;24:83-93
- Albers FC, Müllerová H, Gunsoy NB, et al. Biologic treatment eligibility for real-world patients with severe asthma: the IDEAL study. J Asthma 2018;55:152-60
- Sweeney J, Patterson CC, Menzies-Gow A, et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. Thorax 2016;71:339-46
- Zeiger RS, Schatz M, Li Q, et al. Burden of chronic oral corticosteroid use by adults with persistent asthma. J Allergy Clin Immunol Pract 2017;5:1050-60
- Heffler E, Madeira LNG, Ferrando M, et al. Inhaled corticosteroids safety and adverse effects in patients with asthma. J Allergy Clin Immunol Pract 2018;6:776-81
- Bachert C, Sousa AR, Lund VJ, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol 2017;140:1024-31
- Busse W, Buhl R, Fernandez Vidaurre C, et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol 2012;129:983-9
- Iribarren C, Rahmaoui A, Long AA, et al. Cardiovascular and cerebrovascular events among patients receiving omalizumab: results from EXCELS, a prospective cohort study in moderate to severe asthma. J Allergy Clin Immunol 2017;139:1489-95